TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Teva Pharmaceutical Industries Ltd. Shareholders and a Lead Plaintiff Deadline of October 23, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) who purchased American Depositary Shares between November 15, 2016 and August 2, 2017. The action, which was filed in the United States District Court for the Eastern District of Pennsylvania, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose adverse information concerning the Company’s business and outlook. In particular, it is alleged that Teva failed to disclose and/or omitted the true negative impact of the acquisition and integration of Actavis Generics on the Company’s financial results and business prospects.

Shareholders have until October 23, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/teva-pharmaceutical-industries-ltd?wire=2.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
14/09/2017

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

Teva and Blackstone Life Sciences Announce $400 Million Strategic Grow...

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1ADuvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn’s disease (CD)Agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and drive long-term growth PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutic...

Teva Pharmaceutical Industries Ltd: 1 director

A director at Teva Pharmaceutical Industries Ltd sold 345,810 shares at 33.645USD and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...

 PRESS RELEASE

Teva to Present at the Upcoming Investor Conferences in March

Teva to Present at the Upcoming Investor Conferences in March PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows: UBS European Healthcare Conference Tuesday, March 3, 2026 (investor meetings only – no webcast)Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026, at 10:00 am ET (webcast fireside chat)Barclays 28th Annual Global Healthcare ConferenceTuesday, Mar...

 PRESS RELEASE

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Applic...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treat...

 PRESS RELEASE

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated cli...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch